Cancer Research UK spinout Achilles raises $175.5m in IPOUK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that Share XCancer Research UK spinout Achilles raises $175.5m in IPOhttps://pharmaphorum.com/news/cancer-research-uk-spinout-achilles-raises-175-5m-in-ipo/
Protein misfolding specialist Gain nets $40m from IPOGain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery Share XProtein misfolding specialist Gain nets $40m from IPOhttps://pharmaphorum.com/news/protein-misfolding-specialist-gain-nets-40m-from-ipo/
Rubius launches $200m IPO to fund red blood cell therapiesRubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel Share XRubius launches $200m IPO to fund red blood cell therapieshttps://pharmaphorum.com/news/rubius-launches-200m-ipo-for-red-blood-cell-therapies/
UK biotech investment at record levels amid COVID-19New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last Share XUK biotech investment at record levels amid COVID-19https://pharmaphorum.com/news/uk-biotech-investment-at-record-levels-amid-covid-19/
AI drug discovery biotech AbCellera eyes record IPOAbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and Share XAI drug discovery biotech AbCellera eyes record IPOhttps://pharmaphorum.com/news/ai-drug-discovery-biotech-abcellera-eyes-record-ipo/
UK biotech sector sets new record with more than £1bn investment in Q3There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, Share XUK biotech sector sets new record with more than £1bn investment in Q3https://pharmaphorum.com/news/uk-biotech-sector-sets-new-record-with-more-than-1bn-investment-in-q3/
MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOCompass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy Share XMindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOhttps://pharmaphorum.com/news/mindmed-aims-for-nasdaq-listing-after-compass-magic-mushroom-fuelled-ipo/
Compass plans $100m IPO to fund magic mushroom depression drugUK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its Share XCompass plans $100m IPO to fund magic mushroom depression drughttps://pharmaphorum.com/news/compass-plans-100m-ipo-to-fund-magic-mushroom-depression-drug/
Inozyme plans $75m IPO as it heads for clinic with rare bone diseases drugUS biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a Share XInozyme plans $75m IPO as it heads for clinic with rare bone diseases drughttps://pharmaphorum.com/news/inozyme-plans-75-ipo-as-it-heads-for-clinic-with-rare-bone-diseases-drug/
